OncoMatch/Clinical Trials/NCT06176027
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
Is NCT06176027 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Azacytidine plus CAOLD regimen for relapsed peripheral t-cell lymphomas.
Treatment: Azacytidine plus CAOLD regimen — This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with CAOLD Regimen in the treatment of relapsed/refractory peripheral t-cell lymphomas.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L (≥ 1 x 10^9/L if bone marrow involvement by lymphoma); Platelet ≥ 75 x 10^9/L (≥ 50 x 10^9/L if BM involvement by lymphoma); Hemoglobin ≥ 8 g/dL
Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10^9/L (≥ 1 x 10^9/L if bone marrow (BM) involvement by lymphoma); Platelet ≥ 75 x 10^9/L (≥ 50 x 10^9/L if BM involvement by lymphoma); Hemoglobin ≥ 8 g/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify